Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
16/12/2025 12:06
Dec 16 (Reuters) - Adagene Inc 978y.F: ADAGENE ANNOUNCES FDA FAST TRACK DESIGNATION FOR MUZASTOTUG (ADG126) Source text: ID:nGNX9pPQPD Further company coverage: [978y.F] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate